Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
Billings Clinic · Kyoto University · +4 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
686
total citations
- FWCI
- 28.76
- Percentile
- 100%
- References
- 33
Citations per year
Authors
7Topics & keywords
Topics
Keywords
- Semaglutide
- Medicine
- Placebo
- Tolerability
- Type 2 diabetes
- Randomized controlled trial
- Diabetes mellitus
- Dulaglutide
No related works found for this paper.